Prof. Jordi Mestres holds a Ph.D. in Computational Chemistry from the University of Girona. After a postdoctoral stay at Pharmacia & Upjohn (USA), in 1997 he joined the Molecular Design & Informatics department at N.V. Organon (The Netherlands), and in 2000 he was appointed Head of Computational Medicinal Chemistry at Organon Laboratories (Scotland). In 2003, he took on his current position as Head of Systems Pharmacology at the IMIM Hospital del Mar Medical Research Institute in Barcelona. He is also Associate Professor at the University Pompeu Fabra. In 2006, he founded Chemotargets as a spin- off company from his group. His most recent research interests focus on developing novel systems approaches to gain insights into how small molecules interfere with the human metabolome. He is the author of over 130 publications, with 8 patents among them.
Dr. David Vidal received his Ph.D. in Organic Chemistry from the University of Barcelona in 2006. Under the supervision of Prof. Miquel Pons, he specialized in the design and development of modeling techniques and algorithms for drug discovery. After a postdoctoral stage in Germany, he joined Chemotargets in 2007, where he has contributed to the development of new methods to predict off-target pharmacology and participated in different drug discovery projects, mainly focused on hit identification and hit-to-lead optimization. His scientific interests are focused on the interface between chemistry and biology and, particularly, the understanding of the physicochemical basis of molecular recognition.
Dr. Ricard Garcia-Serna received his BA degree in Biology from the University of Barcelona in 2001. He then obtained a technical degree in Computer Science before attending graduate school at the University Pompeu Fabra, where, in 2010, he earned his Ph.D. in Biomedicine under the supervision of Dr. Jordi Mestres. He then joined Chemotargets, where he is currently responsible for developing new systems approaches to drug safety risk assessment.